Sun Pharma Acquires Organon & Co for $11.8 Billion in Largest-Ever Overseas Pharma Deal by Indian Company
Indian pharma giant to become top 3 player in women's health and seventh-largest biosimilars company globally
L'essentiel
- Sun Pharma, India's largest pharma company, has acquired US-listed Organon & Co for $11.8 billion (Rs 98,000 crore) in an all-cash transaction — the biggest-ever overseas pharma deal by an Indian company.
- Sun Pharma will pay $14 per share, a 24% premium to Organon's closing price.
- The acquisition adds over 140 high-growth markets including China, and portfolio of women's health, biosimilars, and legacy brands.
Résumé généré par IA
Pourquoi c'est important
Sun Pharma has a proven M&A playbook, including the landmark Ranbaxy acquisition in 2014. The company has delivered 14% revenue CAGR between FY10 and FY25. Organon was spun off from Merck in 2021 and brings over 70 products across women's health, general medicines, and biosimilars, along with six manufacturing facilities worldwide.
New Delhi: In its boldest move yet, Sun Pharma, India's largest pharma company, has struck the biggest-ever overseas pharma deal, acquiring US-listed Organon & Co for $11.8 billion (Rs 98,000 crore) in an all-cash transaction. The deal broadens Sun Pharma's therapeutic breadth and geographic reach in one sweep, adding over 140 high-growth markets including China, and a portfolio around innovative therapies, including women's health, biosimilars, and legacy brands. Sun Pharma will pay $14 per share, a premium of over 24% to Organon's last closing price on April 24 in one of the largest M&A deals by an Indian company. On Monday, Sun Pharma shares closed 7% higher at Rs 1,734 on BSE. Indian company now third largest in women's health Once completed, the acquisition will double Sun Pharma's revenue to $12.4 billion and its EBITDA to $3.7 billion, ranking it among the top 25 global pharmaceutical companies. Organon, spun off in 2021 from Merck (known as MSD outside US and Canada), brings portfolio of over 70 products across women's health, general medicines and biosimilars, along with six manufacturing facilities worldwide. The deal follows Sun Pharma's proven M&A playbook from the landmark Ranbaxy acquisition in 2014 to a string of in-licensing deals, which have strengthened its innovative portfolio and delivered a 14% revenue CAGR between FY10 and FY25. Sun chairman Dilip Shanghvi said: "We are debt-averse, but we are never risk-averse. Biosimilars is a segment where building capabilities organically would take years; Organon gives us that platform immediately." The deal positions Sun Pharma as the top 3 player in women's health, after German firms Merck and Bayer, and the seventh-largest biosimilars company in the world -- two of the fastest-growing segments. "Sun Pharma's proposed deal with Organon, valued around 6x EBITDA, appears financially disciplined, supported by steady cash flows," Vishal Manchanda analyst at Systematix said.
À surveiller
Perspective IA — des possibilités, pas des certitudes
Sun Pharma will complete regulatory approvals and close the Organon acquisition within 12-18 months
Probable · En quelques mois
Sun Pharma will integrate Organon's portfolio and manufacturing facilities to expand global footprint
Très probable · En quelques mois
Sun Pharma will become top 3 player in women's health globally, competing directly with Merck and Bayer
Très probable · En quelques mois
Questions ouvertes
- When will the deal be completed?
- What regulatory approvals are needed?
- How will integration be managed?
- Will there be job impacts at Organon facilities?
